Ownership and insider activity for ALX Oncology Holdings Inc. (ALXO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Price
| Price | $1.76 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-17 | Lettmann Jason | S-Sale | 2,230 | $4K |
| 2026-08-17 | Wong Shelly | S-Sale | 573 | $1K |
| 2026-07-01 | Wong Shelly | S-Sale | 1,404 | $3K |
| 2026-04-16 | Knight Jeff E. | A-Award | 800,000 | $1.3M |
| 2026-04-16 | Klencke Barbara | A-Award | 100,000 | $168K |
| 2026-04-13 | Knight Jeff E. | |||
| 2026-03-19 | Lettmann Jason | S-Sale | 12,311 | $27K |
| 2026-03-19 | Pinto Shelly | S-Sale | 903 | $2K |
| 2026-03-03 | Klencke Barbara | A-Award | 700,000 | $1.4M |
| 2026-02-25 | Klencke Barbara |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.3M | $9.0M | $434.2M | $363.7M | $48.8M | $22.4M | $17.6M | $16.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | $217.4M | $160.3M | $110.2M | $28.4M |
| Receivables | $932000 | $536000 | 0 | 0 | 0 | 0 | $892000 | $298000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.2M | $9.8M | $436.0M | $367.0M | $271.0M | $188.7M | $134.4M | $50.7M |
| Property, Plant & Equipment | $956000 | $860000 | $52000 | $3.5M | $9.8M | $10.8M | $9.6M | $1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.2M | $10.7M | $436.1M | $380.2M | $306.5M | $242.6M | $147.8M | $59.0M |
| Accounts Payable | $697000 | $3.7M | $4000 | $3.8M | $8.1M | $8.6M | $4.5M | $4.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $435000 | $5.2M |
| Total Current Liabilities | $1.9M | $5.0M | $6.2M | $15.3M | $28.3M | $36.0M | $18.5M | $24.6M |
| Long-term Debt | 0 | $5.4M | 0 | 0 | $9.4M | $9.6M | $9.5M | 0 |
| Total Liabilities | $2.0M | $11.0M | $6.2M | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Retained Earnings | -$53.5M | -$72.8M | -$118.5M | -$202.0M | -$325.5M | -$486.3M | -$621.1M | -$722.8M |
| Total Equity | $9.2M | -$276000 | $429.8M | $363.0M | $263.5M | $189.7M | $113.6M | $26.0M |
| Total Debt | 0 | $5.4M | 0 | $742000 | $10.4M | $17.2M | $17.0M | $5.2M |
| Net Debt | -$8.3M | -$3.6M | -$434.2M | -$362.9M | -$255.8M | -$165.5M | -$110.8M | -$39.6M |
| Working Capital | $8.3M | $4.8M | $429.8M | $351.7M | $242.6M | $152.7M | $115.9M | $26.2M |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 9.71 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -21.32 |
Profitability
| Return on Equity | -391.42% |
| Return on Invested Capital | -261.95% |
| Return on Assets | -172.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · BCYC · GLUE · KYMR · NKTX · STOK · TNYA
Explore sector: Healthcare · Biotechnology
More sections of ALXO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks